Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr130.10 DKK
Change Today -0.40 / -0.31%
Volume 80.1K
LUN On Other Exchanges
As of 8:24 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (LUN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/15 - kr162.90
52 Week Low
10/14/14 - kr111.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for H LUNDBECK A/S (LUN)

Related News

No related news articles were found.

h lundbeck a/s (LUN) Details

H. Lundbeck A/S researches, develops, produces, and sells pharmaceuticals for the treatment of brain disorders in Denmark and internationally. The company offers pharmaceutical products for the treatment of schizophrenia, major depressive disorder, symptomatic neurogenic orthostatic hypotension, lennox-gastaut syndrome, and alcohol dependence. It also offers other products for the treatment of Alzheimer’s disease, depression and anxiety, Parkinson’s disease, chorea associated with Huntington’s disease, relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, manic episodes associated with bipolar 1 disorder, and refractory complex partial seizures. In addition, the company is involved in the development of Brexpiprazole, a novel investigational psychotherapeutic compound; and Idalopirdine, a potent and selective 5-HT6 receptor antagonist that are in Phase III clinical trails. It has strategic alliances with various companies, including Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Valby, Denmark.

5,859 Employees
Last Reported Date: 05/6/15
Founded in 1915

h lundbeck a/s (LUN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (LUN) Key Developments

H. Lundbeck A/S Presents at Citi European Healthcare Conference, Jun-15-2015

H. Lundbeck A/S Presents at Citi European Healthcare Conference, Jun-15-2015 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Palle Holm Olesen, Chief Specialist of Investor Relations and Vice President of Investor Relations.

H Lundbeck AS Appoints Kare Schultz as President and CEO, Effective as of May 20, 2015

H Lundbeck AS announced the appointment of Kare Schultz as president and CEO, effective as of May 20, 2015. Schultz has an extensive experience in the pharmaceutical industry. He joined Danish drug maker Novo Nordisk in 1989 and was appointed president and chief operating officer (COO) in January 2014. Schultz is also board chairman at Danish brewery group Royal Unibrew A/S and board member at toymaker Lego.

H. Lundbeck A/S Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for 2015

H. Lundbeck A/S announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of DKK 32 million compared to profit from operations of DKK 569 million last year. Revenue was DKK 3,563 million against DKK 3,587 million a year ago. Loss before tax was DKK 32 million against profit before tax of DKK 552 million a year ago. Net loss was DKK 81 million or DKK 0.41 per diluted share against net profit of DKK 331 million or DKK 1.69 per diluted share a year ago. Cash outflows from operating activities were DKK 382 million compared to DKK 151 million a year ago. Investments in intangible assets and property, plant and equipment were DKK 35 million compared to DKK 68 million a year ago. Cash flow per share was DKK 1.94 compared to DKK 0.77 a year ago. Return on equity was negative of 0.6% against 2.5% a year ago. On core basis, profit from operations was DKK 216 million, profit before tax was DKK 216 million and profit for the period was DKK 129 million or DKK 0.66 per share against profit from operations was DKK 729 million, profit before tax of DKK 712 million and profit for the period of DKK 440 million or DKK 2.25 per share a year ago. Return on capital employed was negative 0.2% against 3.7% a year ago. The decline of 10% in local currency and 1% reported is primarily due to the generic competition on Ebixa and Cipralex in Europe and on Cipralex in Canada. For the fiscal year 2015, Lundbeck is expecting constant exchange rate revenue to be in the range DKK 13.2 to DKK 13.7 billion. Lundbeck still expects core profit from operations (core EBIT) in constant exchange rate to be around DKK 0 for 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LUN:DC kr130.10 DKK -0.40

LUN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €17.88 EUR +0.09
Ipsen SA €49.91 EUR +0.24
Meda AB kr115.30 SEK +1.00
Orion Oyj €31.69 EUR -0.30
Recordati SpA €19.06 EUR +0.24
View Industry Companies

Industry Analysis


Industry Average

Valuation LUN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at